Literature DB >> 15093541

Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.

Lambratu Rahman1, Donna Voeller, Monzur Rahman, Stan Lipkowitz, Carmen Allegra, J Carl Barrett, Frederic J Kaye, Maria Zajac-Kaye.   

Abstract

Thymidylate synthase (TS) is an E2F1-regulated enzyme that is essential for DNA synthesis and repair. TS protein and mRNA levels are elevated in many human cancers, and high TS levels have been correlated with poor prognosis in patients with colorectal, breast, cervical, bladder, kidney, and non-small cell lung cancers. In this study, we show that ectopic expression of catalytically active TS is sufficient to induce a transformed phenotype in mammalian cells as manifested by foci formation, anchorage independent growth, and tumor formation in nude mice. In contrast, comparable levels of two TS mutants carrying single point mutations within the catalytic domain had no transforming activity. In addition, we show that overexpression of TS results in apoptotic cell death following serum removal. These data demonstrate that TS exhibits oncogene-like activity and suggest a link between TS-regulated DNA synthesis and the induction of a neoplastic phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093541     DOI: 10.1016/s1535-6108(04)00080-7

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  60 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma.

Authors:  Olga V Danilova; Larry J Dumont; Norman B Levy; Frederick Lansigan; William B Kinlaw; Alexey V Danilov; Prabhjot Kaur
Journal:  J Hematop       Date:  2013-03       Impact factor: 0.196

Review 3.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

4.  Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase.

Authors:  Adam Jarmuła; Tomasz Fraczyk; Piotr Cieplak; Wojciech Rode
Journal:  Bioorg Med Chem       Date:  2010-04-09       Impact factor: 3.641

5.  Evaluation of Thymidylate Synthase Expression in Prostate Cancer.

Authors:  Shoichiro Ohta; Shingo Kamoshida; Akito Tashiro; Kei-Ichi O-Ono; Nobuhiro Yasuno; Yasuo Kamakura; Masanori Yasuda
Journal:  Curr Urol       Date:  2015-11-10

6.  Histone acetylation resulting in resistance to methotrexate in choroid plexus cells.

Authors:  Preethi Prasad; Hernan Vasquez; Chandra M Das; Vidya Gopalakrishnan; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2008-10-14       Impact factor: 4.130

Review 7.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

8.  Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Authors:  Oluf Dimitri Røe; Endre Anderssen; Eli Helge; Caroline Hild Pettersen; Karina Standahl Olsen; Helmut Sandeck; Rune Haaverstad; Steinar Lundgren; Erik Larsson
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

9.  Identification of thymidylate synthase as a potential therapeutic target for lung cancer.

Authors:  K Takezawa; I Okamoto; S Tsukioka; J Uchida; M Kiniwa; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism.

Authors:  Prasun J Mishra; Bo Song; Pravin J Mishra; Yuan Wang; Rita Humeniuk; Debabrata Banerjee; Glenn Merlino; Jingfang Ju; Joseph R Bertino
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.